Novo Nordisk share price rose nearly 5% on August 18, 2025. The hike came after the US Food and Drug Administration granted ...

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...

Expanded approval of Wegovy was based on results from the Phase III ESSENCE trial (NCT04822181), which demonstrated ...

Wegovy becomes the first GLP-1 based therapy authorized for MASH, which affects roughly 5% of U.S. adults, according to the American Liver Foundation. Until now, the only FDA-approved treatment for ...

Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...

The label expansion could help Novo Nordisk “help shift the momentum” for Wegovy, after a difficult start to 2025, according ...

In a significant breakthrough for the treatment of liver disease, Novo Nordisk's Wegovy has received U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in ...

Novo Nordisk’s GLP-1 drug Wegovy expanded its label to include the metabolic disorder known as MASH. Analysts say there’s ...

Novo Nordisk stock jumped Monday after the FDA approved the company's obesity drug, Wegovy, as a treatment for MASH.

In a groundbreaking development, Novo Nordisk's Wegovy has received U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver ...

The string of negative updates from Novo Nordisk and positive news flow from the main competitor Eli Lilly has finally ended ...